Stock 6576 FORESEE PHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Foresee Pharmaceuticals Co., Ltd. Share Price

Equities

6576

TW0006576002

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 03:30:00 26/04/2024 am IST 		5-day change 1st Jan Change
95 TWD -0.11% Intraday chart for Foresee Pharmaceuticals Co., Ltd. +1.50% -1.25%
01/04 Foresee Pharmaceuticals Receives Positive Recommendation from Data and Safety Monitoring Board to Continue the Casppian Study CI
28/03 Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2024 * 916M 28.12M 2.34B Sales 2025 * - Capitalization 12.9B 396M 33.02B
Net income 2024 * -76M -2.33M -195M Net income 2025 * - EV / Sales 2024 * 14.2 x
Net Debt 2024 * 116M 3.56M 297M Net cash position 2025 * - 0 0 EV / Sales 2025 * -
P/E ratio 2024 *
-148 x
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 66.79%
More Fundamentals * Assessed data

Chart Foresee Pharmaceuticals Co., Ltd.

Dynamic Chart

Latest news about Foresee Pharmaceuticals Co., Ltd.

Foresee Pharmaceuticals Receives Positive Recommendation from Data and Safety Monitoring Board to Continue the Casppian Study CI
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Foresee Pharmaceuticals Co., Ltd. Announces Executive Changes, Effective March 31, 2024 CI
Foresee Pharmaceuticals Co., Ltd. Obtains the Official Pharmaceutical License of CAMCEVI 42 Mg from the Ministry of Health and Welfare in Taiwan CI
Foresee Pharmaceuticals Co., Ltd. Announces Last Patient Enrolled in the China Registration Clinical Trial of Leuprolide Injectable Emulsion in Prostate Cancer Has Completed Treatment CI
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Foresee Pharmaceuticals Co., Ltd. Submits Phase 3 IND (Investigational New Drug) Application to China NMPA CI
Foresee Pharmaceuticals Announces First Patient Dosed in the Casppian, Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion, 42 mg for the Treatment of Central Precocious Puberty Patients CI
Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 Activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium CI
Foresee Pharmaceuticals Announces FDA Orange Book Listing of New U.S. Patent for Camcevi®, Extending Patent Protection to 2039 CI
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Ben Liu as Member to the Compensation Committee CI
Foresee Pharmaceuticals to Present Allergic Asthma Study at European Medical Conference MT
Foresee Pharmaceuticals Co., Ltd. Appoints Ben Liu as Audit Committee Member CI
Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Ben Liu as Independent Director CI
More news

Press releases Foresee Pharmaceuticals Co., Ltd.

Foresee Pharmaceuticals Receives Positive Recommendation from DSMB to Continue the Casppian Study, a Phase 3 Clinical Trial of Leuprolide Injectable Emulsion for the Treatment of CPP AQ
Foresee Pharmaceuticals to Present at the American Heart Association Annual Meeting Focusing on its ALDH2 activator FP-045 in Pulmonary Hypertension Associated with Interstitial Lung Disease AQ
Foresee Pharmaceuticals Announces Publication of Preclinical Data in Nature Communications AQ
Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium AQ
Foresee Pharmaceuticals Announces Completion of US$42.3 Million Financing AQ
More press releases

Quotes and Performance

1 day-0.11%
1 week+1.50%
Current month-3.06%
1 month-1.66%
3 months+1.50%
6 months+16.56%
Current year-1.25%
More quotes

Highs and lows

1 week
93.70
Extreme 93.7
95.80
1 month
93.10
Extreme 93.1
101.00
Current year
92.50
Extreme 92.5
107.50
1 year
75.30
Extreme 75.3
107.50
3 years
69.50
Extreme 69.5
141.00
5 years
35.10
Extreme 35.1
141.00
10 years
35.10
Extreme 35.1
141.00
More quotes

Managers and Directors - Foresee Pharmaceuticals Co., Ltd.

Managers TitleAgeSince
Yu Hua Li FOU
 Founder - 09/15/09
Benjamin Chien CEO
 Chief Executive Officer - 08/13/08
Max Chan DFI
 Director of Finance/CFO 56 07/19/07
Members of the board TitleAgeSince
George Lee BRD
 Director/Board Member 73 03/15/03
Benjamin Chien CEO
 Chief Executive Officer - 08/13/08
Fu Shiow Yin BRD
 Director/Board Member - 31/16/31
More insiders

ETFs positioned on Foresee Pharmaceuticals Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +2.14% -
More ETFs positioned on Foresee Pharmaceuticals Co., Ltd.

Quotes

Date Price Change Volume
26/24/26 95 -0.11% 126,877
25/24/25 95.1 0.00% 89,610
24/24/24 95.1 +1.06% 121,376
23/24/23 94.1 +0.11% 131,750
22/24/22 94 +0.43% 198,885

End-of-day quote Taipei Exchange, April 26, 2024

More quotes

Company Profile

Foresee Pharmaceuticals Co., Ltd. is a Taiwan-based company mainly engaged in the research and development of new pharmaceuticals. The Company's main products include prostate cancer treatment product FP-001 and asthmatic/chronic obstructive pulmonary disease treatment product FP-025. It also engages in new pharmaceuticals clinic trial business.
Sector
Biotechnology & Medical Research
Calendar
10/05/2024 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Foresee Pharmaceuticals Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
95 TWD
Average target price
153 TWD
Spread / Average Target
+61.05%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
FORESEE PHARMACEUTICALS CO., LTD. Stock Foresee Pharmaceuticals Co., Ltd.
-1.25% 396M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 6576 Stock